Aquestive Therapeutics, Inc. (AQST) Operating margin 2017–2025
Aquestive Therapeutics, Inc. (AQST) operating margin by fiscal year — reported operating income divided by reported revenue.
-159.5%FY2025 · since FY2017: -0.2% → -159.5%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -159.5% | -106.0 pp |
| FY2024 | -53.5% | -23.6 pp |
| FY2023 | -29.9% | +58.4 pp |
| FY2022 | -88.2% | -20.0 pp |
| FY2021 | -68.2% | +25.3 pp |
| FY2020 | -93.6% | +6.6 pp |
| FY2019 | -100.1% | -27.5 pp |
| FY2018 | -72.6% | -72.4 pp |
| FY2017 | -0.2% | — |
Operating margin = reported operating income ÷ reported revenue for the same fiscal year. Operating-loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice
More AQST financial trends
AQST RevenueAQST Net incomeAQST Net marginAQST Gross profitAQST Gross marginAQST Operating incomeAQST Operating cash flowAQST Free cash flowAQST Capital expendituresAQST Return on equityAQST Stock buybacksAQST Dividends paidAQST Total assetsAQST Total liabilitiesAQST Shareholders’ equityAQST overview →